Foghorn Therapeutics Inc. Stock Price, News & Analysis

Harbinger Health announced the appointment of Ajit Singh, Ph.D. as its new CEO and CEO-Partner of Flagship Pioneering. Singh, who has served on Harbinger's board since 2024, brings extensive diagnostics industry experience, particularly from his tenure at Siemens and leadership in oncology diagnostics companies.

Current CEO Stephen Hahn, M.D. will transition to CEO Emeritus and Special Advisor while maintaining his position on the Board of Directors. The leadership change comes as Harbinger advances its platform for early cancer detection using blood-based tests that analyze proprietary methylation patterns of cell-free ctDNA.

The company recently presented data showing promising results in detecting multiple high-incidence, high-mortality cancers related to obesity, along with platform innovations to enhance cancer signal detection.

Foghorn Therapeutics (Nasdaq: FHTX) released its Q2 2025 financial and corporate update, highlighting significant progress across its clinical pipeline. The company's lead program, FHD-909, a first-in-class SMARCA2 selective inhibitor targeting NSCLC, is progressing well in Phase 1 trials. Preclinical data showed synergistic benefits when combined with pembrolizumab and KRAS inhibitors.

The company reported strong financial position with $198.7 million in cash and equivalents, extending runway into 2028. Q2 2025 saw collaboration revenue of $7.6 million and a reduced net loss of $17.9 million compared to $23.0 million in Q2 2024. Multiple pipeline developments are expected, including the advancement of their Selective CBP degrader program targeting IND in 2026, and updates on EP300 and ARID1B degrader programs in Q4 2025.

Flagship Pioneering has unveiled Terrana Biosciences, a new agricultural technology company developing RNA-based solutions for crop enhancement and protection. The company emerges with an initial $50 million commitment from Flagship Pioneering after four years of platform development.

Terrana's proprietary RNA technology platform enables the development of targeted products that can work throughout a plant's lifecycle, creating solutions that adapt to variable climate conditions. The company has already demonstrated proof of concept in tomatoes, corn, and soy, and generated a pipeline of over 15 potential products in specialty and row crops.

The company's platform leverages AI and computational models to assemble a vast RNA library and design system for creating novel functional crop traits. Their solutions aim to help farmers combat diseases and pests, adapt to climate conditions, and maintain soil health, while offering advantages over conventional approaches in terms of timing flexibility and environmental impact.

Foghorn Therapeutics (NASDAQ: FHTX) has reported its Q1 2025 financial results and corporate updates. The company's lead candidate, FHD-909, is advancing in Phase 1 dose escalation trials for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer. Recent data presented at AACR demonstrated synergistic activity with pembrolizumab and KRAS inhibitors. The company is progressing with multiple pipeline programs, including a Selective CBP degrader (targeting IND in 2026), EP300 degrader, and ARID1B degrader programs, with updates expected in H2 2025.

Financially, Foghorn reported Q1 2025 collaboration revenue of $6.0 million, up from $5.1 million in Q1 2024. Net loss improved to $18.8 million compared to $25.0 million in the prior year. The company maintains a strong balance sheet with $220.6 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing runway into 2027.

Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.

The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.

Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.

Foghorn Therapeutics (FHTX) has appointed two new members to its Board of Directors: Neil Gallagher, M.D., Ph.D., and Stuart Duty. The clinical-stage biotechnology company, which focuses on developing medicines that correct abnormal gene expression, will benefit from their extensive biotechnology industry experience. Both new directors expressed enthusiasm about Foghorn's potential in developing selective therapies for various cancers and its capabilities in selective protein degradation.

Flagship Pioneering and Quotient Therapeutics have appointed Rahul Kakkar, M.D. as CEO-Partner and Chief Executive Officer. Dr. Kakkar brings nearly 20 years of experience in biotech entrepreneurship and medicine, previously serving as CEO of Tome Biosciences and Pandion Therapeutics, which was acquired by Merck for $1.85 billion.

Jake Rubens, Quotient's co-founder and former CEO, will transition to a board director role after successfully establishing the company's first industrial platform for discovering drug targets through somatic genomics and securing a collaboration with Pfizer in cardiovascular and renal diseases.

Dr. Kakkar, who continues to practice at Brigham and Women's Hospital and lecture at Harvard Medical School, will lead Quotient's efforts in advancing its pipeline and platform technology. The company's focus on somatic genomics aims to discover novel drug targets and create first-in-class medicines for various diseases.

Foghorn Therapeutics presented new preclinical data at the 2025 AACR Annual Meeting, highlighting progress across multiple cancer treatment programs. The company's lead candidate, FHD-909, a selective SMARCA2 inhibitor, is advancing in Phase 1 trials targeting SMARCA4-mutated cancers, particularly non-small cell lung cancer (NSCLC).

Key developments include:

• FHD-909 showed enhanced anti-tumor activity when combined with pembrolizumab and KRAS inhibitors
• The Selective CBP degrader program demonstrated promising results in ER+ breast cancer models
• New data on the Selective EP300 degrader program for treating blood cancers
• Progress on the ARID1B degrader program, targeting up to 5% of all solid tumors

The company will host a virtual investor event on April 29, 2025, to review these pipeline updates. FHD-909's Phase 1 trial continues enrollment and dose escalation, with NSCLC as the primary target population, where SMARCA4 mutations occur in up to 10% of cases and often coincide with KRAS mutations.